The human immunodeficiency virus type 1 (HIV-1)-encoded RNA-binding protein Tat is known to play an essential role in viral gene expression. In the search for novel compounds to inhibit Tat transactivity, one coumarin derivative, BPRHIV001, was identified, with a 50% effective concentration (EC 50 ) against HIV-1 at 1.3 nM. BPRHIV001 is likely to exert its effects at the stage after initiation of RNAPII elongation since Tat protein expression and the assembly of the Tat/P-TEFb complex remained unchanged. Next, a reduction of the p300 protein level, known to modulate Tat function through acetylation, was observed upon BPRHIV001 treatment, while the p300 mRNA level was unaffected. A concordant reduction of phosphorylated Akt, which was shown to be closely related to p300 stability, was observed in the presence of BPRHIV001 and was accompanied by a decrease of phosphorylated PDPK1, a well-known Akt activator. Furthermore, the docking analysis revealed that the reduced PDPK1 phosphorylation likely resulted from the allosteric effect of interaction between BPRHIV001 and PDPK1. With strong synergistic effects with current reverse transcriptase inhibitors, BPRHIV001 has the potential to become a promising lead compound for the development of a novel therapeutic agent against HIV-1 infection.
In the replication cycle of human immunodeficiency virus type 1 (HIV-1), the HIV-1-encoded RNA-binding protein Tat can activate long terminal repeat (LTR)-directed gene expression (62) . Unlike most transcriptional activators, Tat functions through binding to TAR, corresponding to the 5Ј end of a nascent transcript initiated at the HIV-1 LTR (7). In the absence of Tat protein expression, the short transcripts are generated from virus-infected cells, yet no detectable virus particles are produced (20) . The optimal activity of Tat is further dictated by its association with two classes of cellular proteins, Tat-associated kinases (TAKs) and Tat-associated histone acetyltransferases (TAHs). TAKs include RNA polymerase II (RNAPII) C-terminal domain (CTD) kinases, positive transcription elongation factor complex b (P-TEFb), and TFIIH. P-TEFb is composed of cyclin T1 (CycT1) and cyclin-dependent kinase 9 (CDK9), which also participate in the binding of Tat to TAR (51, 70) . Tat-mediated recruitment of P-TEFb enhances the processivity of the RNAPII elongation complex, which leads to a considerable increase of viral RNA (76) . Tat itself was also shown to be a substrate of TAHs, including p300/CBP, p300/CBP associating factor (P/CAF), and GCN5 (16, 35, 48) . While P/CAF acetylates Tat on its Lys-28, GCN5 and p300/CBP can acetylate Tat on its Lys-50 and Lys-51. The acetylation of Lys-28 enhances the ability of Tat to recruit the P-TEFb complex, while that of Lys-50 and Lys-51, which is in direct contact with the TAR, leads to its dissociation from TAR (18, 35, 57) . Acetylation of different lysine residues on Tat appears to create a code reminiscent of the histone code, which finely regulates its activity. p300 is an essential transcription factor involved in many intracellular processes, such as regulation of cell cycle, differentiation, and apoptosis (61, 75) . The stability of p300 is believed to be delicately regulated by different proteins, such as p38, Akt, and Skp2 (13, 36, 52) . Among them, repression of the PI3K/Akt pathway causes decreased stability of p300 and subsequent protein degradation (13, 34) . In the PI3K/Akt pathway, the PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the membrane, providing docking sites for 3Ј-phosphoinositide-dependent protein kinase 1 (PDPK1) and Akt (54) . Activation of Akt requires phosphorylation of Thr308 in its activation loop by PDPK1 and subsequent phosphorylation of Ser-473 within the carboxyl-terminal hydrophobic motif by the rictor-mTOR complex (2, 58) . The activation of PDPK1 requires autophosphorylation at Ser-241 on its activation loop, and a single amino acid mutation at Ser-241 abolished its activity (11) .
Previously, a coumarin derivative, identified originally from screening of at least 20,000 compounds for inhibitors of influenza virus (60) , was later found to be effective in inhibiting HIV-1 replication, likely through interfering with Tat-mediated transactivation by our laboratory. An in vitro cell-based screening system, LTR-luciferase reporter system, was established to screen for a series of 291 coumarin derivatives, synthesized by H.-P. Hsieh's group, and 84 of these compounds were found to inhibit more than 80% of Tat transactivity at the concentration of 0.1 M yet had insignificant cytotoxicity to cells. Among those, the most potent coumarin derivative, the PBMCs were washed, RPMI medium with fresh 10% FBS and 10 U/ml interleukin-2 (IL-2) (PeproTech Inc., NJ) alone or with the indicated concentration of test compounds was added. Infected cells were maintained for 7 days, during which time, an aliquot of culture supernatants was collected, and fresh medium with or without test compounds was added at days 3 and 5, respectively. The cells were harvested at day 7. The amount of viruses in the supernatants was determined by the HIV-1 p24 ELISA kit.
Quantitative real-time RT-PCR. Viral RNA was extracted from 140 l virus supernatant by the use of the Qiagen viral RNA extraction kit (Qiagen, Hilden, Germany) and was subjected to reverse transcription (RT) using a random hexamer. The derived cDNA was used to amplify HIV-1 LTR with the condition described previously (42) by the use of the ABI Prism 7700 Fast real-time PCR system (Applied Biosystems, CA). A standard curve for the quantification of the HIV-1 viral load was generated using serial dilutions of the NL4-3 plasmid, and the detection range was 2 to 2 ϫ 10 6 copies. RT-PCR. Total RNA was extracted using the TRIzol reagent (Invitrogen, CA) and was subjected to reverse transcription using LTR-R or oligo(dT) primers. The primer pair for amplification of HIV-1 LTR was LTR-F (5Ј-GTC TCT GGT TAG ACC AGA T-3Ј; nucleotides [nt] 456 to 472 at LTR) and LTR-R (5Ј-GAA GCA CTC GGC AAG CTT TA-3Ј; nt 538 to 550 at LTR), and the PCR amplification condition was 95°C for 1 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s. The primer pair for amplification of the p300 HAT domain was p300-HAT-F (5Ј-CGT CAA CCT GTG GAC CCT CAG C-3Ј; nt 3621 to 2642 at p300) and p300-HAT-R (5Ј-GCT CTT ATT TTT GCT GGT TTT C-3Ј; nt 5057 to 5078 at p300), and the PCR amplification condition was 95°C for 1 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and elongation at 72°C for 90 s. The expected sizes of PCR products are 95 bp and 1,457 bp for HIV-1 LTR and the HAT domain of p300, respectively. One-tenth of the PCR products were resolved on an agarose gel. The signal strength of PCR products was semiquantitated by ImageJ (http://rsb.info.nih.gov/ij/).
Cytotoxicity assay. The cytotoxicity of test compounds in PBMC was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. Briefly, PBMCs were seeded into a 96-well culture plate at the concentration of 1 ϫ 10 5 cells per well. Maintenance medium containing different concentrations of test compounds was added. After 7 days of incubation, cells were spun down at 150 ϫ g for 10 min (Allegra X-15R centrifuge; Beckman Coulter, CA). After the medium was removed, MTT reagent (0.1 mg/ml) (SigmaAldrich, NY) was added and incubated for 5 h at 37°C. Then, MTT reagent was removed, and dimethyl sulfoxide (DMSO) was added for another 10-min incubation. Then, the absorbance was determined by the SpectraMax M5 microplate luminometer (Molecular Devices, CA) at 595 nm. The percentage of inhibition was calculated using the following formula: % inhibition ϭ [100 Ϫ (A t /A s ) ϫ 100]%, where A t and A s refer to the absorbance of test substances and solvent control, respectively. The 50% cytotoxicity concentration (CC 50 ) was defined as the concentration reducing 50% of cell viability.
Dual-luciferase reporter assays. 293T cells were plated onto 6-well plates (2.5 ϫ 10 5 cells/well) 1 day before transfection. The next day, cells were cotransfected with 0.05 g pRK5-Tat, 1 g pGL2-LTR, and 0.01 g pRL-TK using Lipofectamine 2000 reagent (Invitrogen, CA). Cell medium was replaced with fresh medium with or without test compounds at 4 h posttransfection. Forty hours after transfection, total cell lysates were harvested for determination of luciferase activity using the dual-luciferase reporter assay system (Promega, WI) and the SpectraMax M5 microplate luminometer (Molecular Devices, CA).
Coimmunoprecipitation. Nuclear extracts were obtained from transfected cells. After preclearing with protein G agarose beads (Pierce, Thermo Scientific, IL) at 4°C for 4 h, the precleared nuclear extracts were recovered after centrifugation at 12,000 ϫ g at 4°C for 10 min (Allegra 64R centrifuge; Beckman Coulter, CA). The precleared nuclear extracts were then incubated with antiFlag monoclonal antibody (F3165; Sigma-Aldrich, NY) or anti-CDK9 polyclonal antibody (sc-7331; Santa Cruz, CA) at 4°C. After overnight incubation, protein G agarose beads (Pierce, Thermo Scientific, IL) were added and incubated for 24 h at 4°C. The supernatants were removed after centrifugation at 2,500 ϫ g at 4°C for 2 min (Allegra 64R centrifuge; Beckman Coulter, CA), and the beads were carefully washed three times with IP buffer (20 mM Tris-HCl [pH 8.0], 1 mM EDTA, 100 mM NaCl, and 0.5% [vol/vol] Nonidet P-40). Finally, the beads were resuspended in 2ϫ SDS sample buffer (125 mM Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, and 2% ␤-mercaptoethanol) and analyzed by Western blotting.
Western blotting. Total cell lysates were prepared using lysis buffer containing 50 mM (pH 7.4) Tris-HCl, 1% Nonidet P-40, 150 mM NaCl, 2.5% deoxycholate, 1 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor (SigmaAldrich, NY). Nuclear extracts and total cell lysates were mixed with 4ϫ SDS sample buffer before loading the gel for SDS-PAGE. Northern blotting. Total RNA was extracted from cell pellets using TRIzol reagent (Life Technologies, CA) and quantified by ND-1000 (NanoDrop Technologies, DE). Next, equal amounts of RNA samples were resolved on a 1% formaldehyde agarose gel, transferred, and cross-linked to a nylon membrane (Perkin Elmer, CA) using the UVC-500 irradiator (Hoefer Pharmacia Biotech, CA) at a dose of 120 mJ/cm 2 . Hybridization and probe preparation were performed using the DIG Northern starter kit (Roche Applied Science, IN). The oligonucleotide probes for detecting luciferase and actin mRNA were 3Ј end labeled with digoxigenin (DIG), and purified by the Gel-M gel extraction system (Viogene, Taipei, Taiwan). Hybridization signals were determined by the Fuji LAS-4000 luminescent image analyzer (Fujifilm Life Science, MA).
Immunofluorescence confocal microscopy. 293T cells were seeded onto circular glass coverslips (12 mm; Assistent, Hecht, Sondheim, Germany) and maintained in 24-well plates. Next day, cells were cotransfected with 0.05 g pRK5-Tat, 1 g pGL2-LTR, and 0.01 g pRL-TK using Lipofectamine 2000 reagent (Invitrogen, CA). Cell medium was replaced with fresh medium with or without test compounds at 4 h posttransfection. At indicated time, cells were washed with PBS, fixed with 4% paraformaldehyde, and blocked with 1% bovine serum albumin (BSA) in PBS. The coverslips were then incubated for 1 h at 37°C with anti-PDPK1 antibody (no. 1901; Epitomocs, CA) and anti-p-PDPK1 (Ser-241) (no. 2895; Epitomocs, CA). After that, cells were washed 4 times before incubation for 1 h at 37°C with Cy3-conjugated secondary antibodies. The cells were washed and stained with 1 g/ml 4Ј-6-diamidino-2-phenylindole (DAPI; SigmaAldrich, NY) for another 20 min at room temperature. The coverslips were mounted and analyzed using the confocal microscope (Leica TCS SP2 spectral confocal system with a 63ϫ oil immersion lens and numerical aperture [NA] of 1.32; Wetzler, Germany). The data were collected with 4-fold averaging at a resolution of 512 by 512 pixels.
In vitro enzyme assay for PDPK1. Human recombinant protein kinase PDPK1 expressed in Sf21 insect cells was used to test its in vitro enzyme activity in the presence of different compounds. First, BPRHIV001 was preincubated with 400 ng/ml PDPK1 in modified MOPS (morpholinepropanesulfonic acid) buffer (pH 7.2, 25 mM MOPS, 12.5 mM ␤-glycerol-phosphate, 25 mM MgCl 2 , 5 mM EGTA, 2 mM EDTA) for 15 min at 37°C. Next, the reaction was initiated by addition of 5.3 M PDKtide, 10 M ATP, and 0.25 Ci [␥- [46] , 2XCK [4] , 2VKI [6] , and 1W1D [37] ) were used as a template for the homology modeling building. All the calculations were performed using Discovery Studio 2.1 (DS 2.1) (Accelrys, Inc., San Diego, CA). The active sites were defined by the DS receptor-ligand interactions program. The docking analysis was conducted using the DS Ligfit program with the CHARMm force field (10) . To make sure that the modeling structure was in equilibration, the DS simulation program was used. The minimization convergent was performed by the two-step method. The first step was steepest descent, with minimization root mean square (RMS) gradient convergence to 0.1, and the final step was conjugate gradient, with minimization RMS gradient convergence to 0.0001. Except for the production parameter being set as 200,000 steps, other parameters were used as the default. All the minimization processes were calculated with the distance-dependent dielectrics environment. After these molecular dynamics procedures, the binding energy was calculated by the DS program for calculating binding energies. The active residue analysis was conducted using the Ligplot program (67) . The site-directed mutant method was performed using the DS program for building mutants, and all mutant residues were changed to alanine.
Analysis of drug interaction. The degree of interaction between drugs was evaluated by two methods. First, the degree of drug interaction was presented in terms of isoboles, or isoeffect curves (i.e., concentration pairs that have the same level of effect) (65) . Briefly, the effect of two drugs used in combination was evaluated by generating a dose-responsive curve for drug A in the presence of various concentrations of drug B and vice versa. For instance, D DRUGA is the amount of drug A producing an effect (e.g., EC 50 of drug A). When the additivity relationship is satisfied between drug A and drug B, the isobole should be a straight line connecting points (D DRUGA , 0) and (0, D DRUGB ). Accordingly, a concave isobole indicates synergy, and a convex isobole indicates antagonism between drug A and drug B (39) . Second, the fractional inhibitory concentration (FIC) index (FICI) method was used to evaluate the interaction between drugs (26). It was calculated using the following equation: FICI ϭ FIC A ϩ FIC B ϭ X A /E A ϩ X B /E B , where E A and E B are the EC 50 s of drugs A and B when used alone and X A and X B are the concentrations of drug A and drug B at its isoeffective concentration (i.e., 50% inhibition of viral RNA copies) (1). The interaction between drugs A and B was determined based on the FICI number: synergy (Ͻ0.5), no interaction (0.5 to 4), or antagonism (Ͼ4) (47) .
Statistical analysis. All statistical analyses were performed using SPSS software, version 11.0 (SPSS). A 2-sample t test was used for the comparison of continuous variables, with correction of unequal variances when appropriate. The significance level was set at 0.05, and all P values were two tailed.
RESULTS
Interference of Tat-mediated transactivation by BPRHIV001. In the search for novel compounds inhibiting Tat transactivity, an in vitro cell-based assay system using luciferase as a reporter gene under the control of LTR was established. Some coumarin derivatives were found to exhibit inhibitory effects on Tat-mediated transactivation. Among those, BPRHIV001 exhibited a remarkable inhibitory effect, and its chemical structure is depicted in Fig. 1A . A significant and dose-dependent inhibitory effect of BPRHIV001 was observed at the concentration within a nanomolar range, whereas the DMSO solvent control did not cause any inhibition (Fig. 1B) . The Tat protein used in this study is a 86-amino-acid truncated form. To confirm that BPRHIV001 also inhibits the activity of the fulllength 101-amino-acid Tat, a plasmid expressing the full-length Tat protein was constructed and its activity in the presence of BPRHIV001 was examined. As expected, a comparable inhibitory effect of BPRHIV001 was observed when the full-length Tat was used (see In addition, similar inhibitory effects of BPRHIV001 on Tat amplified from other HIV-1 subtypes, CRF01_AE and CRF07_BC, were observed (see Fig. S2B at the URL mentioned above).
Since, for genes under the control of LTR, Tat-mediated transactivation is essential for the processivity of RNAPII, Northern blotting was subsequently performed to determine if BPRHIV001 indeed affected Tat-mediated transcription at the mRNA level. As shown in Fig. 1C , a dose-dependent decrease of the luciferase mRNA level was observed in the presence of BPRHIV001, while the mRNA level of ␤-actin remained unaffected. These data suggested that BPRHIV001 could specifically inhibit Tat-mediated transactivation.
No disruption of TAK complex by BPRHIV001. The inhibition of Tat-mediated transactivation was unlikely attributed to reduction of either Tat protein expression or TAR expression, since similar amounts of Tat protein ( Fig. 2A ) and TAR RNA (Fig. 2B) were observed with the BPRHIV001-treated and the control groups.
Next, the immunoprecipitation assay was performed to determine whether the association of Tat and P-TEFb, composed of cyclin T1 (CycT1) and cyclin-dependent kinase 9 (CDK9), which is essential for the processivity of RNAPII, was interrupted in the presence of BPRHIV001. Due to the low expression levels of CDK9 and CycT1 in 293T cells, the correspond-ing expression plasmids were transfected into 293T cells. As shown in Fig. 2C , comparable amounts of CycT1 and Tat were immunoprecipitated in the presence or absence of BPRHIV001, and the relative ratios of these proteins in the immunoprecipitated complex remained constant. Based on these data, the assembly of the transcriptional elongation machinery was less likely to be disrupted by BPRHIV001.
Reduction of p300 protein level by BPRHIV001. p300/CBP could acetylate Tat on Lys-50 and Lys-51, which leads to the dissociation of Tat from TAR (18, 35, 57) and subsequent recycling of Tat. The physiological level of p300 was also shown to be critical for the Tat activation of integrated HIV-1 LTR in HeLa cells (9) . Therefore, further experiments were conducted to determine the role of p300 in BPRHIV001-directed inhibi- Total cell lysates were harvested at 40 h after cotransfection of pRK5-Tat, pGL2-LTR, and pRL-TK plasmids into 293T cells in the presence or absence of BPRHIV001. The luciferase activity was measured using the dual-luciferase reporter assay system. The pRL-TK plasmid was used as a transfection control. Values in this figure represent the mean of three independent experiments, with its respective standard deviation indicated. The asterisk ( * ) designates a statistically significant difference (P Ϲ 0.05) between the test group and the DMSO solvent control. (C) Reduced Tat-derived mRNA levels in the presence of BPRHIV001. After cells were cotransfecetd with pRK5-Tat, pGL2-LTR, and pRL-TK plasmids, the total RNA was extracted and then separated by electrophoresis. The expression levels of luciferase and ␤-actin mRNA were determined by Northern blotting using the DIG Northern starter kit. The relative expression of luciferase mRNA normalized by ␤-actin mRNA is shown individually.
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on October 25, 2017 by guest http://jvi.asm.org/ tion of Tat-mediated transactivation. First, when p300 siRNA was transfected to downregulate p300 protein expression, more than half of the Tat-mediated transactivation activity was inhibited, implicating the significance of the p300 protein level in Tat-mediated transactivation (Fig. 3A) . Next, a significant reduction of the p300 protein level (approximately 61% of the p300 level detected in the control, P ϭ 0.018) was observed in the presence of BPRHIV001 (Fig. 3B) . On the contrary, as illustrated in Fig. 3C , no significant difference was observed with the p300 mRNA levels between BPRHIV001 and the control groups, indicating that BPRHIV001 influences the p300 protein level at the stage after transcription. Next, the involvement of p300 in BPRHIV001-mediated inhibition of Tat activity was investigated using a Tat K50E mutant, which was previously shown not to be acetylated by p300, yet remained relatively transcriptionally active (33) . As shown in Fig. 3D , the Tat K50E mutant exhibited half of the wild-type Tat transactivation activity. In the presence of 4 nM BPRHIV001, the Tat K50E mutant was relatively resistant to BPRHIV001-mediated inhibition (12% inhibition for the Tat K50E mutant versus 60% inhibition for the wild-type Tat, P ϭ 0.001). Even in the presence of 10-fold BPRHIV001, only 37% of Tat K50E transactivity was inhibited compared to the 80% inhibition observed with the corresponding wild-type Tat (Fig. 3D) . Similar inhibitory effects were observed when the mutant was constructed in the backbone of 101-amino-acid Tat (see Fig. S3 posted at http://www.mc.ntu.edu.tw/department /clsmb/sychang/supplementary_data/ Fig.S3 .pdf). These data suggested that BPRHIV001 might exert its inhibitory effects through regulation of p300.
Regulation of p300 expression through the PI3K/Akt pathway by BPRHIV001. p300 stability is delicately modulated by its interactions with different proteins. Among them, repression of the PI3K/Akt signaling pathway could reduce its stability and subsequently lead to its protein degradation (13) . Since Akt is a downstream effector of the PI3K/Akt pathway, the protein level of phosphorylated Akt, the active form of Akt, was first determined by Western blotting. As shown in Fig.  4A , while the total Akt protein level remained unchanged, the level of phosphorylated Akt was reduced in the presence of BPRHIV001 in a dose-dependent manner. Next, the involvement of a negative regulator in the PI3K/Akt pathway, phosphatase tensin homolog (PTEN) (63) , in BPRHIV001-mediated inhibitory effects was evaluated. As shown in Fig. 4B , comparable amounts of PTEN were observed with BPRHIV001 and the control groups. Therefore, BPRHIV001 is likely to reduce the p300 protein level through repressing the PI3K/Akt pathway independent of PTEN.
Reduction of PDPK1 phosphorylation by BPRHIV001. PDPK1 is crucial for Akt phosphorylation, and its autophosphorylation at residue Ser-241, which is located on the activation loop of the PDPK1 kinase domain, is required for its activity (11) and subsequent trafficking to the plasma membrane to interact with PIP3 (3, 64) . The proper orientation of PDPK1 at the membrane upon stimulation by pervanadate, hydrogen peroxide, and insulin leads to further phosphorylation at Tyr-9 and Tyr-373/376 to increase its enzyme activity (50, 53) . Therefore, the level of phosphorylated PDPK1 was determined by Western blotting. As shown in Fig. 4C , a significant reduction of Ser-241 and Tyr-373/376 phosphorylation forms was observed in the presence of BPRHIV001, while the amount of total PDPK1 remained unchanged. Because the Ser-241 phosphorylation is required for its membrane localization, immunofluorescence confocal microscopy was performed to confirm this finding. In Fig. 4D , whereas the expression level of total PDPK1 was similar in both the BPRHIV001-treated and the control groups, the majority of PDPK1 in the BPRHIV001-treated group was distributed within the nucleus and the cytoplasm, in contrast to the cytoplasmic membrane localization observed in the control group. Also, the protein level of Ser-241-phosphorylated PDPK1 was decreased in the presence of BPRHIV001, a finding consistent with pre- FIG. 3 . Reduction of p300 protein levels by BPRHIV001. (A) Reduction of Tat-mediated transactivation activity by p300 siRNA (si-p300). 293T cells were transfected with p300 siRNA. Twenty-four hours after transfection, cells were cotransfected with 0.05 g pRK5-Tat, 1 g pGL2-LTR, and 0.01 g pRL-TK. Forty hours after transfection, total cell lysates were harvested for determination of p300 protein expression and luciferase activity. The relative expression of p300 normalized by PCNA was shown individually. si-nons, nonspecific siRNA. (B) Reduced p300 protein levels in the presence of BPRHIV001. The p300 protein levels in cells treated with different amounts of BPRHIV001 were determined by Western blotting. The relative expression of p300 normalized by PCNA was shown individually. The location of the suspected p300 protein was detected above the 250-kDa marker, indicated in the corresponding bright-field image on the right. pCMV-p300, RNA extracted from pCMV-p300 plasmid-transfected cells. (C) Steady p300 mRNA levels in the presence of BPRHIV001. RT-PCR was performed to determine the amounts of p300 mRNA in the presence or absence of BPRHIV001. RNA extracted from pCMV-p300 plasmid-transfected cells was used as a positive control (labeled pCMV-p300). The negative controls include RNA extracted from p300-siRNA-transfected cells (labeled si-p300) and reaction mixtures without cDNA input (labeled as NC). The relative expression of p300 normalized by ␤-actin is shown individually for each condition. (D) Resistance of the Tat K50E mutant to BPRHIV001-mediated inhibition. Total cell lysates were harvested at 40 h after cotransfection of indicated pRK5-Tat or Tat K50E mutant, pGL2-LTR, and pRL-TK plasmids in the presence or absence of BPRHIV001. The luciferase activity was measured using the dual-luciferase reporter assay system. The pRL-TK was used as a transfection control. and Ser-241-phosphorylated PDPK1 by confocal microscopy. 293T cells were cotransfected with pRK5-Tat, pGL2-LTR, and pRL-TK. BPRHIV001 was added into culture medium at 4 h posttransfection. After the indicated time, cells were harvested and fixed. PDPK1 and phosphorylated PDPK1 (Ser-241) were detected by anti-PDPK1 and anti-phosphorylated PDPK1 (Ser-241) primary antibodies followed by donkey anti-rabbit Cy3-conjugated secondary antibodies. The cells were counterstained for nuclei with DAPI. Confocal microscopy was performed, and the data were collected with 4-fold averaging at a resolution of 512 by 512 pixels. Reduction of Tat-mediated transactivation activity by Akt1 siRNA (E) and PDPK1 siRNA (F). 293T cells were transfected with Akt1 and PDPK1 siRNA, respectively. Twenty-four hours after transfection, cells were cotransfected with 0.05 g pRK5-Tat, 1 g pGL2-LTR, and 0.01 g pRL-TK. Total cell lysates were harvested at 40 h after transfection for determination of protein expression and luciferase activity. The ratios of each protein normalized by PCNA, PDPK1, or Akt are shown separately below the gel image.
vious Western blotting data. Furthermore, an in vitro assay was performed to determine the inhibitory effects of BPRHIV001 on PDPK1, and a 87% reduction of Ser/Thr kinase activity of PDPK1 was observed in the presence of 10 M BPRHIV001.
To further confirm that the reduction of Akt1 and PDPK1 active forms could decrease the p300 protein level and subsequently lead to reduced Tat-mediated transactivation, siRNAs specific for Akt1 and PDPK1 were introduced. As shown in Fig. 4E and F, Tat-mediated LTR transactivity was inhibited by 51% and 47% in the presence of Akt1 and PDPK1 siRNA, respectively. In cells transfected with Akt1 siRNA, a reduction of Akt and p300 protein levels was observed, while the levels of PDPK1 remained unchanged (Fig. 4E) . In cells transfected with PDPK1 siRNA, a significant decrease of PDPK1, Akt, and p300 protein levels was observed (Fig. 4F) . Overall, these data suggested that the presence of BPRHIV001 is likely to influence PDPK1 autophosphorylation, which subsequently leads to decreased phosphorylation of Akt and the instability of its downstream effector, p300.
Docking analysis of BPRHIV001 with PDPK1. PDPK1 is known to have two domains, the catalytic domain and the PH domain (8, 37) . To investigate the location of the BPRHIV001-binding site on PDPK1, the PDPK1 whole-protein structure was constructed by the homology modeling method (Fig. 5A) . By applying the Discovery Studio 2.1 tool predictions protocol and the docking strategy, the active sites in PDPK1 were shown as the green and red Jacks formation, with red indicating the potential binding sites for BPRHIV001. The possibility that BPRHIV001 might compete with ATP at the ATP binding site, like most PDPK1 inhibitors, was excluded, since the binding energy of BPRHIV001 at site A, the binding site for ATP, was much higher than that of ATP (Ϫ57.53 Kcal/mol versus Ϫ319.25 Kcal/mol) (see Table S1 posted at http://www.mc.ntu .edu.tw/department/clsmb/sychang/supplementary_data/ TableS1.pdf). Previous studies have demonstrated that PDPK1 has a hydrophobic pocket termed the "PIF pocket," which plays a key role in mediating certain signaling pathways by activating AGC kinases (8) . A compound PS48 has been used as an activator by Hindie et al. to study the phosphorylationdependent conformational changes (29) . By taking PS48 as a control ligand to dock into the PIF pocket in our model structure, the estimated energy of BPRHIV001 binding to the PIF pocket was Ϫ51.62 Kcal/mol, which was quite the same as that of PS48, with the value of Ϫ54.51 Kcal/mol (see Table S1 posted at the URL mentioned above). The BPRHIV001 interactive residues in PDPK1 were Lys-115, Ile-118, Ile-119, Val-127, and Arg-131 (Fig. 5B1) , which had been proven as active residues by site-directed mutagenesis (8, 29) . Therefore, it is possible that the binding of BPRHIV001 to the PIF pocket could affect PDPK1 phosphorylation. Furthermore, BPRHIV001 could also bind to site B with a binding energy of Ϫ61.91 Kcal/mol. When BPRHIV001 binds to site B, an allosteric effect could be induced to influence the ATP binding site on PDPK1 (Fig. 5C ). Hydrophobic interaction was involved between PDPK1 and BPRHIV001 through Trp-347, His-395, Trp-397, Gly-409, Ser-410, and Glu-434 residues (Fig. 5B2) . When these residues were switched to alanine individually in silico, significant changes in binding energy were noticed for residues Trp-347, His-395, and Gly-409 (see Table   S2 posted at http://www.mc.ntu.edu.tw/department/clsmb /sychang/supplementary_data/TableS2.pdf), suggesting the involvement of these residues in the PDPK1 and BPRHIV001 interaction.
Inhibition of HIV-1 replication by BPRHIV001. After we demonstrated that BPRHIV001 could strongly inhibit Tat-mediated transactivity, the anti-HIV replication activity of BPRHIV001 was examined. The presence of BPRHIV001 could significantly diminish the viral output in the supernatants at day 7 post-HIV infection, with one log reduction at 4 nM (Fig. 6A) . In this assay, BPRHIV001 exhibited an inhibitory effect against HIV replication similar to that of azidothymidine (AZT), one of the reverse transcriptase inhibitors used for HIV therapy. The inhibitory effect was not derived from its solvent, DMSO, whose presence had no inhibitory effect on virus replication. The effects of BPRHIV001 on HIV replication and cell viability were further examined (Table 1 ). In PBMCs, BPRHIV001 inhibited HIV replication with an EC 50 of 1.3 nM, and its 50% cytotoxicity concentration (CC 50 ) was 1.3 M. The derived selective index (SI) of BPRHIV001 to HIV-1 was 1,000. The inhibitory effects of BPRHIV001 were also examined with two HIV-1 clinical isolates, one of subtype B (p128) origin and one of CRF07_BC (p117) origin. As shown in Table 1 , BPRHIV001 inhibited the virus replication of both, with EC 50 s of 1.0 nM and 2.4 nM, respectively.
As demonstrated above, BPRHIV001 may repress virus replication by reducing p300 protein levels. The influence of p300 downregulation in HIV-1 replication was examined by transfecting p300 siRNA to U87-CD4 ϩ -CXCR4 ϩ cells. In p300 siRNA-transfected cells, reduction in both the p300 protein levels (63% reduction) and the virus titer (35% reduction, P ϭ 0.01) was observed (Fig. 6B) , which indicates that virus replication could be suppressed by silencing endogenous p300.
Further, the inhibitory effects of BPRHIV001 against HIV-1 strains resistant to two currently used antiretrovirals, AZT and EFV, were examined. The EC 50 s of BPRHIV001 against EFVand AZT-resistant viruses was 0.9 nM and 3.9 nM, respectively (Table 1 ). These data indicated that the target of BPRHIV001 is indeed different from HIV-1 reverse transcriptase, the target of AZT and EFV. The combinatory effects of BPRHIV001 with AZT or EFV were determined using isobologram analysis and the fractional inhibitory concentration index (FICI) method. A synergy between BPRHIV001 and AZT or EFV was observed using the isobologram analysis (Fig. 7) and the FICI method (AZT, FICI ϭ 0.164 to 0.384; EFV, FICI ϭ 0.07 to 0.4), demonstrating the great promise of coadministering BPRHIV001 with either of these two drugs for future HIV therapy.
DISCUSSION
The introduction of highly active antiretroviral therapy (ART) (HAART) has significantly prolonged the survival and reduced the mortality and morbidity of HIV-1-infected persons (19, 45, 49) . However, the widespread use of ART has resulted in the emergence of antiretroviral drug resistance (55) , whose existence in HIV-1-infected patients could seriously compromise virological response to ART (25, 40, 66) . The transmission of antiretroviral-resistant viruses was observed and resulted in the acquirement of drug resistance in treatment-naive patients (32, 59, 71, 72) . Furthermore, the choice for second-line regimens after the development of antiretroviral drug resistance is often complicated by cross-resistance and drug-drug interaction (22) . Therefore, the development of an antiviral against the novel target is essential for HIV therapy. In the present study, a coumarin derivative, BPRHIV001, was found to possess a strong antiviral activity against HXB2 and AZT-and EFV-resistant viruses and also displayed synergistic effects with the RT inhibitors. BPRHIV001 was shown to exhibit inhibitory effects against Tat-mediated transactivation. The inhibitory effect is likely derived from reduced phosphorylated PDPK1, which subsequently leads to decreased phosphorylation of Akt and repressed p300 protein levels. A mechanistic model for the inhibitory activity of BPRHIV001 against Tat-mediated transactivation is thus proposed (Fig. 8) .
The p300 protein, a histone acetyltransferase, is well known for its ability to facilitate chromatin remodeling and to regulate gene expression involved in the cell cycle, proliferation, and differentiation (61) . Originally, the association of Tat with p300 was believed to only induce activation of chromatinized HIV-1 LTR through acetylation of histones. Nevertheless, Tat itself was later shown to be a substrate for p300/CBP (48) , and a correlation between a reduced p300 level and abrogated Tat The asterisk ( * ) designates a statistically significant difference (P Ϲ 0.05) between the test condition and the medium-only control. (B) Inhibition of HIV-1 replication by p300 siRNA. Twenty-four hours after p300 siRNA transfection, U87-CD4 ϩ -CXCR4 ϩ cells were infected with HIV-1. The culture supernatants were harvested after 3 days, and the supernatant p24 was determined by the p24 ELISA kit. The p300 protein levels in cell pellets were determined by Western blotting. The ratios of p300 protein normalized by PCNA are shown separately below the gel image. Given the essential role of p300 in maintaining cellular functions, the toxicity of BPRHIV001 cannot be ignored. However, the present data have shown that the CC 50 of BPRHIV001 was within a micromolar range, approximately 1,000 times higher than its EC 50 . The long-term cytotoxicity of BPRHIV001 in PBMCs was further examined. As shown in Fig. S4A posted at http://www.mc.ntu.edu.tw/department /clsmb/sychang/supplementary_data/ Fig.S4 .pdf, no obvious cytotoxicity was observed after the exposure of PBMCs to 40 nM BPRHIV001 for 23 days. Next, a cell cycle analysis was performed to determine the influence of BPRHIV001 on cells, since previous analysis had demonstrated that the cell cycle was abrogated in the absence of p300 or after p300 blockage by a specific antibody (31, 61) . In our preliminary results, the cell cycle progression was not interrupted at the EC 50 of BPRHIV001 (see Fig. S4B posted at the URL mentioned above). These data suggest that the influence of BPRHIV001 on primary cells is relatively limited at a low concentration. Inhibition of Akt phosphorylation in the PI3K/Akt pathway has been shown to result in p300 reduction (13) . Our data demonstrated that BPRHIV001 also repressed Akt phosphorylation, which might result in reduction of p300 and subsequent decreased Tat transactivity. The PI3K/Akt pathway has been shown to be essential for the survival of HIV-1-infected macrophages upon stress, and such cytoprotective effects were found to be mediated by HIV-1 Tat (14) . Tat was shown to mediate downregulation of PTEN, a negative regulator in the PI3K/Akt pathway, by competing with PTEN for p53 binding, which results in p53 destabilization and subsequent reduced PTEN expression. Although BPRHIV001 is less likely to regulate Tat-mediated transactivation by interfering with PTEN expression since the protein levels of PTEN and p53 remained unchanged in the presence of BPRHIV001 ( Ser-241-phosphorylated PDPK1 has been shown to be required for full activation of Akt (11) . In our observation, the decreased Ser-241-phosphorylated PDPK1 level might be responsible for the reduced Tat transactivity. PDPK1 is constitutively autophosphorylated in vivo at Ser-241, which is located on the activation loop of the PDPK1 kinase domain. The Ser-241 autophosphorylation is required for PDPK1 activation (11) and subsequent trafficking to the plasma membrane to interact with PIP3 (3, 64) . Most PDPK1 inhibitors were found to inhibit PDPK1 activity through binding to its ATP binding site on the catalytic domain and result in the repression of Ser-241 autophosphorylation (21, 38) , yet the involvement of the pleckstrin homology (PH) domain of PDPK1 in autophosphorylation of PDPK1 was also addressed (24) . A novel Akt/ PDPK1 inhibitor, PHT-427, was shown to abolish PDPK1 activity through binding to the PH domain (44) . We have attempted to use docking analysis to examine the possibility that binding of BPRHIV001 on PDPK1 could result in reduced autophosphorylation. Our results suggested that BPRHIV001 might bind either site B or the PIF pocket in the catalytic domain of PDPK1 (Fig. 5) . The binding of BPRHIV001 to site B is likely to further induce an allosteric effect in the ATP binding site, which then leads to reduced ATP binding and subsequently reduced phosphorylation of PDPK1. A further experiment is ongoing to examine whether BPRHIV001 inhib- FIG. 8 . Mechanistic model for BPRHIV001-mediated inhibition of Tat transactivation. In the PI3K/Akt pathway, PI3K converts PIP2 to PIP3 at the cell membrane, providing docking sites for PDPK1 and Akt. PTEN, a negative regulator of PI3K/Akt pathway, can reverse PIP3 to PIP2. Activation of Akt requires the phosphorylation of Thr308 in its activation loop by PDPK1, and the activated Akt can prevent p300 from degradation. In the presence of BPRHIV001, the phosphorylation of PDPK1 is repressed, thus leading to reduced Akt activity and a subsequent decrease of p300 protein levels. Besides PDPK1, the PI3K/Akt pathway could be negatively regulated by other proteins, such as carboxyl-terminal modulator protein (CTMP), which could bind specifically to the carboxyl-terminal regulatory domain of Akt at the plasma membrane and subsequently reduce Akt activity by inhibiting phosphorylation at Ser-473 and Thr-308 (43) . At this moment, we could not exclude the possibility that CTMP is also involved in BPRHIV001-regulated Akt activity. Nevertheless, even if it is, our data demonstrated that the activity of PDPK1, the kinase which can phosphorylate and activate Akt at the stage upstream of that at which CTMP could exert its effects, was blocked by BPRHIV001.
Several compounds that possess anti-HIV activity in vitro, such as quinoline derivatives TR-87, K-37, and WM5, stilbene derivative CGA137053, and substituted purines (5, 27, 30, 56, 74) , have been identified as inhibiting Tat transactivity by obstructing Tat/TAR binding, whereas others, such as flavopiridol, roscovitine, and indirubin-3Ј-monoxime (12, 28, 68) , were shown to inhibit Tat transactivity by targeting the p-TEFb component CDK9. Based on our finding, BPRHIV001 could inhibit Tat function through modulating the PI3K/Akt pathway, which has been shown to be essential in HIV replication (17, 23) . In addition, the PI3K/Akt pathway is also related to the HIV-1-induced extension of the life span of infected macrophages, which serve as HIV-1 reservoirs (14) , and to HIV-1-induced neuropathogenesis (73) . How the activation of the PI3K/Akt pathway contributes to HIV replication is relatively unclear at this moment, but our data provide one potential linkage that inactivation of the PI3K/Akt pathway could lead to reduced Tat transactivity, essential for HIV replication. Whether BPRHIV001 could function like some Akt inhibitors, such as alkylphospholipid compounds (41) , to restrain the HIV-1-induced extension of the life span in infected macrophages remains to be resolved and will be an interesting topic to investigate since the clearance of the HIV reservoir represents one challenging obstacle in HIV therapy.
In summary, we demonstrated that BPRHIV001 displayed strong inhibitory effects on HIV-1 Tat-mediated transactivation, possibly through repressing the PI3K/Akt pathway. With an EC 50 of 1.3 n⌴ against HIV, BPRHIV001 not only overcame AZT-and EFV-resistant virus replication but also exhibited a synergistic interaction with AZT and EFV, current anti-HIV agents. It is ensured that BPRHIV001 has the potential to be a promising lead compound for the development of novel therapeutic agents against HIV infection.
